Cymbalta: Dual the Reuptake, Triple the Hype
The Carlat Psychiatry Report, Volume 2, Number 1, January 2004
https://www.thecarlatreport.com/newsletter-issue/tcprv2n1/
Issue Links: | Editorial Information
Topics: Antidepressants
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
We have some good news and we have some bad news. First, the good news: Cymbalta (generic name: duloxetine) is an effective dual reuptake antidepressant with a good safety profile. Now, the bad news: it appears to have no advantages over existing antidepressants.
You can't view details of this content, please login or buy subscription here